Related Experiment Video
Updated: Aug 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
Yunkai Xie1, Weimin Kong1, Xiaoling Zhao1
1Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Abstract:
Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer.
Insights
Immune checkpoint inhibitors (ICIs) offer promising treatment for cervical cancer, improving outcomes for patients with recurrent or metastatic disease. This review covers current knowledge and clinical trial applications of ICIs in cervical cancer therapy.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Cervical cancer is a significant global health concern for women.
- Current treatments for recurrent or metastatic cervical cancer have limited long-term success.
Purpose of the Study:
- To review the current understanding of immune checkpoint inhibitors (ICIs).
- To summarize the application of ICIs in clinical trials for cervical cancer treatment.
Main Methods:
- Literature review of clinical trials and research on immune checkpoint inhibitors.
- Analysis of efficacy and application of ICIs in cervical cancer therapy.
Main Results:
- Immune checkpoint inhibitors (ICIs) demonstrate encouraging efficacy in treating cervical cancer.
- ICIs are approved for both first- and second-line therapies.
Conclusions:
- ICIs represent a significant advancement in cervical cancer treatment.
- Further research and clinical application of ICIs are crucial for improving patient prognosis.
More Related Videos
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Inhibition of Cdk Activity
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...